CXCL8 and neoplasm: Additionally, the EP4 inhibitor suppresses pro-inflammatory cytokine IL-6, chemokine CXCL8, and inflammation-dependent bone metastasis, while alleviating immune suppression and restoring anti-tumor immunity (66).